Photocure ASA: Disclosure of large shareholdings - proxies received in connection with the AGM
27 avr. 2016 03h45 HE
|
Photocure ASA
Oslo, 27 April 2016: Photocure ASA (OSE: PHO). Reference is made to the stock exchange release disclosed 26 April 2016, regarding proxies received by Bente-Lill Bjerkelund Romøren in connection...
Photocure ASA: Disclosure of large shareholdings - proxies received in connection with the AGM
26 avr. 2016 05h54 HE
|
Photocure ASA
Oslo, 26 April 2016: Photocure ASA (OSE: PHO). Bente-Lill Bjerkelund Romøren has as chairperson of the board of directors of PHO received proxies to vote for 1,288,250 shares at the annual general...
Photocure ASA: New analysis shows Hexvix®/Cysview® significantly prolongs time to progression of bladder cancer
26 avr. 2016 02h00 HE
|
Photocure ASA
Photocure ASA Oslo, Norway, 26th April 2016: Photocure ASA (OSE: PHO), is pleased to announce publication of a new analysis demonstrating that Blue Light Cystoscopy (BLC) with Hexvix/Cysview...
Photocure ASA: Share option program
06 avr. 2016 11h29 HE
|
Photocure ASA
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...
Photocure ASA: Annual accounts
06 avr. 2016 10h44 HE
|
Photocure ASA
Oslo, 6 April 2016: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2015. The annual accounts and annual report for the financial year 2015 are...
Photocure ASA: Notice of the annual general meeting 28 April 2016
06 avr. 2016 10h40 HE
|
Photocure ASA
Oslo, 6 April 2016: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 28 April 2016 at 17:00 hours (CET). The notice...
Photocure announces grant of patents for Cevira®
15 mars 2016 03h00 HE
|
Photocure ASA
Oslo, 15 March 2016 - Photocure (OSE: PHO), a specialty pharmaceutical company with focus on photodynamic technologies in cancer and dermatology today announces that a new patent for Cevira has been...
Photocure ASA Hexvix® data presented during the European Association of Urology congress
14 mars 2016 04h03 HE
|
Photocure ASA
Hexvix real world evidence show improved recurrence free survival and health care savings Oslo, Norway, 14 March 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on...
Photocure ASA: Exercise of employee share options
23 févr. 2016 02h03 HE
|
Photocure ASA
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...
Photocure ASA: Results for fourth quarter and full year 2015
10 févr. 2016 17h07 HE
|
Photocure ASA
Oslo, Norway, 11 February 2016: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the fourth quarter...